Frontiers in Clinical Drug Research – Hematology is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies. Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology.<br/> <br/> <br/> <br/>The fifth volume of this series features 7 reviews with a focus on thalassemia treatment and preeclampsia among other topics.<br/> <br/> <br/> <br/>- Recent advances in the diagnosis and management of pulmonary embolism<br/> <br/>- An evidence-based approach to treatment with iron chelators in transfusion- dependent thalassemia patients: present trends and future scenario<br/> <br/>- Current and future treatments of iron overload in thalassemia patients<br/> <br/>- Preeclampsia: biological and clinical aspects<br/> <br/>- Haematological modulations by fixed dose combination (FDC) of tramadol hydrochloride/paracetamol (THP)<br/> <br/>- Possible use of eculizumab in critically ill patients infected with covid-19 role of complement c5, neutrophils, and nets in the induction DIC, sepsis, and MOF hematological markers<br/> <br/>- Emerging diagnostic and therapeutic targets in preeclampsia